Item 8.01. Other Events.



On August 22, 2021, BeiGene, Ltd. announced that the Center for Drug Evaluation
(CDE) of the China National Medical Products Administration (NMPA) has accepted
a supplemental Biologics License Application (sBLA) for anti-PD-1 antibody
tislelizumab in combination with chemotherapy as a first-line treatment for
patients with recurrent or metastatic nasopharyngeal cancer (NPC). The full text
of this press release is filed as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene Announces

Acceptance of a Supplemental


                          Biologics License Application in China for

Tislelizumab in Nasopharyngeal


                          Cancer", issued by BeiGene, Ltd. on August 22, 2021.

       104                The cover page from this Current Report on Form 8-K, formatted in Inline
                          XBRL





--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "    BeiGene Announces

Acceptance of a Supplemental


                          Biologics License Application in China for

Tislelizumab in Nasopharyngeal


                          Cancer    ", issued by BeiGene, Ltd. on August

22, 2021.


       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses